A comprehensive medication review of a polypharmacy patient population: A cross-sectional observational study
Background: It is well documented that polypharmacy status is associated with manifold drug-related problems (DRPs). In this cross-sectional observational study, a type 1 medication review of a polypharmacy patient population in Greece was carried out. Objectives: The study aim was to quantify the p...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2022-06-01
|
| Series: | Exploratory Research in Clinical and Social Pharmacy |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2667276622000439 |
| _version_ | 1811288110847229952 |
|---|---|
| author | Frantzeska Nimee James Steier Georgios Papandreou Maria Skouroliakou |
| author_facet | Frantzeska Nimee James Steier Georgios Papandreou Maria Skouroliakou |
| author_sort | Frantzeska Nimee |
| collection | DOAJ |
| description | Background: It is well documented that polypharmacy status is associated with manifold drug-related problems (DRPs). In this cross-sectional observational study, a type 1 medication review of a polypharmacy patient population in Greece was carried out. Objectives: The study aim was to quantify the prevalence of unaddressed DRPs in a representative Greek polypharmacy patient population. The secondary aim was to report on the average monthly medication cost per polypharmacy study patient. Methods: The study population consisted of 91 older, high-risk polypharmacy patients registered at 10 community pharmacies in Athens. The cross-sectional medication review was conducted by 10 independent pharmacists during September of 2020. DRPs were assessed and classified according to ‘The PCNE Classification V 5.01’ by two clinical pharmacists and researchers. Results: A median concurrent use of 8.45 medications per patient was found, with an average of 1.89 identified DRPs per study subject. A total of 172 DRPs were observed in the study population. 75.6% of all DRPs were classified as drug-drug interaction problems, with a mean of 1.42 identified drug-drug interactions per study subject. The mean monthly cost per polypharmacy patient was calculated at €38.64 ($45.20 USD). Conclusion: There is urgent need to improve in-pharmacy medication monitoring and advising to optimize drug concordance and to reduce DRPs among polypharmacy patients in Greece. Further research is warranted to investigate larger scale polypharmacy-related iatrogenic harm potential due to overlooked and unaddressed DRPs within Europe and globally. Investigation into the predictors of and risk factors for DRP incidence in polypharmacy patient populations is also needed. Broadly, this study underscores the need for continuous and perspicacious monitoring of unaddressed DRPs in patients using multiple drugs by community pharmacists. |
| first_indexed | 2024-04-13T03:31:23Z |
| format | Article |
| id | doaj.art-2532901d3336428da0307970cbb447a2 |
| institution | Directory Open Access Journal |
| issn | 2667-2766 |
| language | English |
| last_indexed | 2024-04-13T03:31:23Z |
| publishDate | 2022-06-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Exploratory Research in Clinical and Social Pharmacy |
| spelling | doaj.art-2532901d3336428da0307970cbb447a22022-12-22T03:04:28ZengElsevierExploratory Research in Clinical and Social Pharmacy2667-27662022-06-016100144A comprehensive medication review of a polypharmacy patient population: A cross-sectional observational studyFrantzeska Nimee0James Steier1Georgios Papandreou2Maria Skouroliakou3Department of Dietetics and Nutritional Science, School of Health Science and Education, Harokopio 6 University, 70 El. Venizelou Ave., 17671 Kallithea, Athens, GreeceTrinity College Dublin, Ireland; Corresponding author.CibusMed, Advanced health and Nutrition solutions, GreeceAssistant Professor in Enteral and Parenteral, Department of Dietetics and Nutritional Science, School of Health Science and Education, Harokopio 6 University, 70 El. Venizelou Ave., 17671 Kallithea, Athens, GreeceBackground: It is well documented that polypharmacy status is associated with manifold drug-related problems (DRPs). In this cross-sectional observational study, a type 1 medication review of a polypharmacy patient population in Greece was carried out. Objectives: The study aim was to quantify the prevalence of unaddressed DRPs in a representative Greek polypharmacy patient population. The secondary aim was to report on the average monthly medication cost per polypharmacy study patient. Methods: The study population consisted of 91 older, high-risk polypharmacy patients registered at 10 community pharmacies in Athens. The cross-sectional medication review was conducted by 10 independent pharmacists during September of 2020. DRPs were assessed and classified according to ‘The PCNE Classification V 5.01’ by two clinical pharmacists and researchers. Results: A median concurrent use of 8.45 medications per patient was found, with an average of 1.89 identified DRPs per study subject. A total of 172 DRPs were observed in the study population. 75.6% of all DRPs were classified as drug-drug interaction problems, with a mean of 1.42 identified drug-drug interactions per study subject. The mean monthly cost per polypharmacy patient was calculated at €38.64 ($45.20 USD). Conclusion: There is urgent need to improve in-pharmacy medication monitoring and advising to optimize drug concordance and to reduce DRPs among polypharmacy patients in Greece. Further research is warranted to investigate larger scale polypharmacy-related iatrogenic harm potential due to overlooked and unaddressed DRPs within Europe and globally. Investigation into the predictors of and risk factors for DRP incidence in polypharmacy patient populations is also needed. Broadly, this study underscores the need for continuous and perspicacious monitoring of unaddressed DRPs in patients using multiple drugs by community pharmacists.http://www.sciencedirect.com/science/article/pii/S2667276622000439PolypharmacyCommunity pharmacyClinical pharmacyMedication reviewGreeceGreek pharmacy |
| spellingShingle | Frantzeska Nimee James Steier Georgios Papandreou Maria Skouroliakou A comprehensive medication review of a polypharmacy patient population: A cross-sectional observational study Exploratory Research in Clinical and Social Pharmacy Polypharmacy Community pharmacy Clinical pharmacy Medication review Greece Greek pharmacy |
| title | A comprehensive medication review of a polypharmacy patient population: A cross-sectional observational study |
| title_full | A comprehensive medication review of a polypharmacy patient population: A cross-sectional observational study |
| title_fullStr | A comprehensive medication review of a polypharmacy patient population: A cross-sectional observational study |
| title_full_unstemmed | A comprehensive medication review of a polypharmacy patient population: A cross-sectional observational study |
| title_short | A comprehensive medication review of a polypharmacy patient population: A cross-sectional observational study |
| title_sort | comprehensive medication review of a polypharmacy patient population a cross sectional observational study |
| topic | Polypharmacy Community pharmacy Clinical pharmacy Medication review Greece Greek pharmacy |
| url | http://www.sciencedirect.com/science/article/pii/S2667276622000439 |
| work_keys_str_mv | AT frantzeskanimee acomprehensivemedicationreviewofapolypharmacypatientpopulationacrosssectionalobservationalstudy AT jamessteier acomprehensivemedicationreviewofapolypharmacypatientpopulationacrosssectionalobservationalstudy AT georgiospapandreou acomprehensivemedicationreviewofapolypharmacypatientpopulationacrosssectionalobservationalstudy AT mariaskouroliakou acomprehensivemedicationreviewofapolypharmacypatientpopulationacrosssectionalobservationalstudy AT frantzeskanimee comprehensivemedicationreviewofapolypharmacypatientpopulationacrosssectionalobservationalstudy AT jamessteier comprehensivemedicationreviewofapolypharmacypatientpopulationacrosssectionalobservationalstudy AT georgiospapandreou comprehensivemedicationreviewofapolypharmacypatientpopulationacrosssectionalobservationalstudy AT mariaskouroliakou comprehensivemedicationreviewofapolypharmacypatientpopulationacrosssectionalobservationalstudy |